Treatment News : Numerous Studies Show Benefit of Earlier HIV Treatment

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 15, 2013

Numerous Studies Show Benefit of Earlier HIV Treatment

Pooled evidence from multiple research studies shows that beginning antiretrovirals (ARVs) to treat HIV when CD4 cells are at or above 350 is beneficial when compared with beginning therapy between 200 and 349 CD4s, the National AIDS Treatment Advocacy Project reports. Evidence also seems to suggest that those who go on ARVs immediately instead of waiting until CD4s drop below 500 have improved survival rates. Investigators presented the findings of their systematic review of available research at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

The researchers pooled results from 13 observational studies that compared the risk of death between those who began ARVs when their CD4s were at or above 350 with those who began therapy with CD4s between 200 and 349. Those who began therapy earlier saw their mortality risk drop by 34 percent, although one randomized controlled trial’s mortality rate reduction was not statistically significant.

The investigators also examined nine observational studies that found an overall 28 percent reduced risk of death or AIDS for those who began therapy on the earlier side of the 350 CD4 mark. Another pair of randomized controlled studies yielded a 52 percent reduced risk of AIDS or death for those beginning therapy earlier.

The data was less definitive about the apparent benefit of beginning ARVs before CD4s hit 500. Four observational studies found no mortality risk reduction. Another five observational studies that compared beginning ARVs immediately after diagnosis with waiting for CD4s to drop below 500, however, found an overall 22 percent reduced mortality risk. This figure was on the cusp of statistical significance.

To read the NATAP report, click here.

Search: HIV, early therapy, antiretrovirals, CD4 count, 200 to 349, 350, 500, National AIDS Treatment Advocacy Project, 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, IAS 2013.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.